The Patent Finder
US

Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof

US 12,583,903 In force
OverviewFamilyAssignmentsSources & methods

Term ends Feb 8, 2038 · Low confidence

Filed Jun 3, 2022 as application 17/831,637 · Granted Mar 24, 2026
Base term plus 759 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
2018 2038
Clock starts
Feb 8, 2018
Term ends
Feb 8, 2038
Granted
Mar 24, 2026
base term Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
759
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 11,066,457, US 11,472,858, US 11,608,369, US 11,618,778, US 12,747,279.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 759 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: Low. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Feb 8, 2018, when application PCT/CN2018/075867, the earliest non-provisional in its chain, was filed (this one was filed Jun 3, 2022); a parent in its chain could not be resolved (the next row)Feb 8, 2038High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustment+759 days, USPTO patent term adjustment recordMar 8, 2040High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 11,066,457, US 11,472,858, US 11,608,369, US 11,618,778, US 12,747,279)capped to Feb 8, 2038High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events0 of 2 maintenance fees paidIn forceHigh confidence
Further caveats on recordThe record names parents not resolved: 16484482, 16484482Low confidence overallLow confidence
Computed term endThe steps above, in orderFeb 8, 2038Low confidence

This family

US 11,066,457In force
Feb 2038
Feb 2038
US 11,472,858In force
Feb 2038
Feb 2038
US 11,618,778In force
Feb 2038
Feb 2038
US 11,608,369In force
Feb 2038
Feb 2038
US 12,583,903this patent
Feb 2038
Feb 2038
US 12,747,279In force
Feb 2038
Feb 2038
Application 18/263,050Pending
not computed
not computed
7 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 3, 2022
Reel 60099, frame 363
Yao, Yihong; Huang, Jiaqi; Zhu, Shigui; Zhu, Wei; Yao, Xin; Li, Zhiyuan; Zhang, Li; Zhu, Lin; Ma, Anyun; Wei, Yutian; Li, Yanfeng; Wang, Qingxia; He, JiapingCellular Biomedicine Group (Shanghai) Ltd.; Cellular Biomedicine Group (Wuxi) Ltd.Assignment of Assignor's Interest
Jun 3, 2022
Reel 60099, frame 458
Cellular Biomedicine Group (Shanghai) Ltd.Cellular Biomedicine Group HK LimitedAssignment of Assignor's Interest
Jun 3, 2022
Reel 60099, frame 542
Cellular Biomedicine Group (Wuxi) Ltd.Cellular Biomedicine Group HK LimitedAssignment of Assignor's Interest
Jun 3, 2022
reel/frame not recorded
He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, WeiCellular Biomedicine Group (Shanghai) Ltd.Assignment of Assignor's Interest
Jun 3, 2022
reel/frame not recorded
He, Jiaping; Huang, Jiaqi; Li, Yanfeng; Li, Zhiyuan; Ma, Anyun; Wang, Qingxia; Wei, Yutian; Yao, Xin; Yao, Yihong; Zhang, Li; Zhu, Lin; Zhu, Shigui; Zhu, WeiCellular Biomedicine Group (Wuxi) Ltd.Assignment of Assignor's Interest
Dec 15, 2022
Reel 62105, frame 405
Cellular Biomedicine Group HK Ltd.Cellular Biomedicine Group Inc.Assignment of Assignor's Interest
Jan 19, 2024
Reel 66356, frame 108
Cellular Biomedicine Group, Inc.Abelzeta Inc.Change of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited